|
|
|
Expression information for ASH2L (Homo sapiens)
(Information derived after consensus based scoring of curated data)
|
| Tissue/Sub tissue | Condition/Sub Condition | Expression status | Reliability score | References |
| Endometrium | Endometrial cancer | Transcribed | 282 | | | Cervix | Cervical cancer | Transcribed | 270 | | | Uterus | Normal | Transcribed | 90 | | | Uterus | Leiomyoma | Transcribed | 68 | | | Cervix | Normal | Transcribed | 56 | | | Endometrium | Normal | Transcribed | 14 | | | Uterus | Leiomyosarcoma | Transcribed | 10 | | | Myometrium | Normal | Transcribed | 10 | | | Endometrium | Endometriosis | Transcribed | 2 | | | Uterus | CIN/Cervical dysplasia | Dormant | 6 | | |
NGS based expression information for ASH2L (Homo sapiens)
(Information from literature curation)
|
| Study | Condition | Expression status |
Llorens et al. Multiple platform assessment of the EGF dependent transcriptome by microarray and deep tag sequencing analysis.
BMC Genomics 2011 Jun 23;12:326. | EGF treated
vs.
untreated control HeLa cells | No change |
Lebedeva et al. Transcriptome-wide analysis of regulatory interactions of the RNA-binding protein HuR.
Mol Cell 2011 Aug 5;43(3):340-52. | ELAVL1/HuR knock down
vs.
mock knockdown HeLa cells | Not available |
Yang et al. Genomewide characterization of non-polyadenylated RNAs.
Genome Biol. 2011;12(2):R16. | Poly A(-)
vs.
ploy A(+) RNA fraction of HeLa cells | Down-regulated |
|
EST based expression for ASH2L (Homo sapiens)
(Information obtained from UniGene database)
|
|
|
